Teladoc (NYSE: TDOC) stock is sinking in Thursday's trading on the heels of the company's recent fourth-quarter release. The telehealth specialist's share price was down 11.7% as of 2:45 p.m. ET and had been off as much as 19.7% earlier in the daily session.
Teladoc published its Q4 results after the market closed yesterday, delivering a mixed report. While the company's sales came in ahead of Wall Street's expectations, the business posted a wider-than-anticipated loss. Management's guidance for this year also underwhelmed investors.
Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »
Teladoc stock tumbles on wider-than-expected Q4 loss
Teladoc posted another quarter of sales declines in Q4, with revenue declining 3% year over year in the period. The business recorded a loss of $0.28 per share on revenue of $640.49 million in the quarter. For reference, the consensus Wall Street estimated had called for a loss of $0.22 per share on revenue of $639.44 million.
Teladoc's integrated care customer count actually increased 5% year over year in Q4, but average revenue per user declined 2%. With signs of weakening pricing power and a loss that came in bigger than anticipated, investors are selling out of the telehealth stock today.
What's next for Teladoc?
Teladoc is guiding for sales to come in between $2.468 billion and $2.576 billion this year. The midpoint of the company's guidance range suggests a roughly 1.9% decline from the sales of roughly $2.57 billion it posted last year. Meanwhile, the company guided for its annual loss per share to come in between $0.50 and $1.10 -- improving from last year's loss of $5.87 per share.
While Teladoc is cutting costs and reducing its losses, the company's growth engine has stalled -- and it's not clear what catalysts on the near horizon might be capable of reinvigorating it. Following botched acquisitions and massive write-downs over the last five years, the company's path to profitability and healthy sales growth looks challenging.
Should you invest $1,000 in Teladoc Health right now?
Before you buy stock in Teladoc Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Teladoc Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $804,553!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of February 24, 2025
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Teladoc Health. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
